Slideshow

Nephritis Sets in Early in Lupus, Treatment Guidelines Can Stave Off Worsening Condition

By the time a patient is diagnosed with SLE, nephritis has already set in for 35 percent of patients. The American College of Rheumatology offers screening, treatment and management guidelines for lupus nephritis patients. In this slideshow, we review the options.

By the time a patient is diagnosed with systemic lupus erythematosus (SLE), nephritis has already set in for approximately 35 percent of patients. And, within 10 years, the number climbs to 50-60 percent of patients. The very presence of lupus nephritis reduces survival from 92 percent at 10 years to 88 percent, according to one estimate. The American College of Rheumatology offers screening, treatment and management guidelines for lupus nephritis patients. In this slideshow, we review the options.UPDATE:  First-Ever Treatment for Lupus Nephritis Wins FDA Approval 

References:

Hahn B, McMahon M, Wilkinson A, Wallace WD, Daikh D, Fitzgerald J, Karpouzas G, Merrill J, Wallace D, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi S, Gogia M, Kafaja S, Kamgar M, Lau C, Martin W, Parikh S, Peng J, Rastogi A, Chen W, Grossman J, American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care & Research (2012), doi: 10.1002/acr.21664

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.